Summary: The researchers are doing this study to find out whether giving 177Lu-PSMA-617 followed by a type of radiation therapy called SBRT (stereotactic body ...
The primary objective of this clinical trial is to assess the effcacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.
VISIT
This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.
VISIT
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) in Men With Hormone Sensitive Prostate Cancer and Rise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)
VISIT
The primary goal of this clinical trial is to determine if adding mevrometostat to the standard therapy (enzalutamide) is more effective in treating metastatic castration-sensitive prostate cancer compared to enzalutamide alone with a placebo.
VISIT
The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The primary objective of this clinical trial is to assess the efficacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC), which will be compared to standard treatments alone (either enzalutamide…
VISIT
The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
VISIT
